AstraZeneca sells cancer drug duo rights to Juvisé
20th Dec 2019 07:30
(Sharecast News) - AstraZeneca on Friday said it had agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) to Juvisé Pharmaceuticals in several European, African and other countries.
Read moreAstraZeneca offloads 'Seroquel' rights in Europe and Russia
16th Dec 2019 07:42
(Sharecast News) - AstraZeneca has completed an agreement to divest its commercial rights to Seroquel - quetiapine fumarate immediate release - and Seroquel XR - quetiapine fumarate extended release - in Europe and Russia, it announced on Monday, to Cheplapharm Arzneimittel.
Read moreThursday broker round-up
12th Dec 2019 13:38
(Sharecast News) - Synthomer: JP Morgan upgrades to neutral with a target price of 300p.
Read moreAstraZeneca gets Imfinzi approval in China
12th Dec 2019 07:32
(Sharecast News) - AstraZeneca announced on Thursday that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for 'Imfinzi' - durvalumab - for the treatment of patients with unresectable, stage 3 non-small cell lung cancer (NSCLC), whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).
Read moreTuesday broker round-up
10th Dec 2019 08:29
(Sharecast News) - ASOS: HSBC upgrades to buy with a target price of 3,615p.
Read moreDeepMatter shares surge as it announces AstraZeneca collaboration
9th Dec 2019 14:07
(Sharecast News) - DeepMatter shares surged on Monday, after it announced a collaboration with AstraZeneca to use digital technologies to improve the productivity and reproducibility of compound synthesis.
Read moreAstraZeneca's Lynparza approved for use in China
5th Dec 2019 08:27
(Sharecast News) - Biopharmaceutical company AstraZeneca announced on Thursday that Lynparza had been approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
Read moreAstraZeneca sells Seroquel rights in US and Canada
3rd Dec 2019 07:29
(Sharecast News) - AstraZeneca has agreed to sell the commercial rights to 'Seroquel' - quetiapine fumarate immediate release - and 'Seroquel XR' - quetiapine fumarate extended release - in the United States and Canada to Cheplapharm Arzneimittel, it announced on Tuesday.
Read moreAstraZeneca Imfinzi treatment gets FDA priority review
29th Nov 2019 07:05
(Sharecast News) - AstraZeneca said the US Food and Drug Administration had accepted a supplemental Biologics License Application (sBLA) and granted priority review for its Imfinzi treatment of patients with previously untreated extensive-stage small cell lung cancer.
Read moreFriday broker round-up
15th Nov 2019 13:09
(Sharecast News) - Whitbread: Barclays upgrades to overweight with a target price of 4,900p.
Read moreShoreCap stays at 'buy' on AstraZeneca after EU approves Qtrilmet
15th Nov 2019 11:25
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation on shares of AstraZeneca following news that Brussels had approved its Qtrilmet treatment for controlling blood sugar levels in patients suffering from Type-2 diabetes.
Read moreAstraZeneca gets EC approval for type-2 diabetes treatment
15th Nov 2019 07:28
(Sharecast News) - AstraZeneca announced on Friday that the European Commission has approved 'Qtrilmet' - metformin hydrochloride, saxagliptin and dapagliflozin - modified-release tablets to improve glycaemic control in adults with type-2 diabetes.
Read moreFDA accepts new drug application for AstraZeneca's selumetinib
14th Nov 2019 07:37
(Sharecast News) - AstraZeneca, along with its partner MSD, announced on Thursday that the US Food and Drug Administration (FDA) has accepted a new drug application (NDA) and granted 'Priority Review' status for selumetinib, as a potential new medicine for paediatric patients aged three years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
Read moreTuesday broker round-up
12th Nov 2019 13:31
(Sharecast News) - BBA Aviation: HSBC downgrades to hold with a target price of 330p.
Read moreAstraZeneca's anifrolumab succeeds in lupus study
12th Nov 2019 08:05
(Sharecast News) - Biopharmaceutical giant AstraZeneca's anifrolumab demonstrated superiority across multiple efficacy endpoints versus placebos in the drug's Phase III TULIP 2 trial.
Read more